Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurobindo Pharma Gets USFDA Nod For Flucytosine Capsules","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"May 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Transgene","sponsor":"Tasly BioPharmaceuticals","pharmaFlowCategory":"D","amount":"$22.2 million","upfrontCash":"Undisclosed","newsHeadline":"Transgene Receives $22.2 Million from the Sale of Part of its Minority Stake in Tasly BioPharmaceuticals","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"FRANCE","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Transgene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Data From a Phase 1 Trial With Transgene\u2019s Oncolytic Virus TG6002","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"FRANCE","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Transgene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Transgene Presents Initial Phase I Data of TG6002, Highlighting the Potential of the Intravenous Administration of Its Oncolytic Viruses","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"FRANCE","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Transgene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Readouts for Transgene\u2019s Clinical Stage Candidates Generated by its Two Innovative Platforms, with Further Clinical Data Expected in the Second Half of 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Denovo Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"United States Food and Drug Administration (FDA) Authorizes Phase 2 Study of DB107 In Promising Turn-Around of Targeted Treatment to Treat Newly Diagnosed High Grade Glioma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Strides receives USFDA Approval for Flucytosine Capsules","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"April 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals for Fluocytosine

    Menu

    Fluocytosine

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PRICE INFORMATION

    INTERMEDIATES

    DOSSIERs // Finished Dosage Forms

    DRUG PRODUCT COMPOSITION

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    GLOBAL SALES INFORMATION

    MARKET PLACE

    ANALYTICAL SOLUTION(s)

    DIGITAL CONTENT

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Strides Pharma Science

              Contact Supplier
              • Development Update
              Virtual BoothStrides Pharma Science: Pioneering IP-driven formulations for niche finished dosage forms.
              Contact Supplier Contact Supplier
              Flag India
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Strides receives USFDA Approval for Flucytosine Capsules

              Details:

              USFDA approved generic version of Flucytosine Capsule (thymidylate synthetase inhibitor) indicated for treating serious infections caused by susceptible strains of Candida and/or Cryptococcus (meningitis and pulmonary infections)

              Lead Product(s): Fluocytosine

              Therapeutic Area: Infections and Infectious Diseases Product Name: Ancobon-Generic

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 20, 2020

              Strides Pharma Science

              CPhI Worldwide, Milan

              Booth #5C33

              envelop Contact Supplier

              Denovo Biopharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              United States Food and Drug Administration (FDA) Authorizes Phase 2 Study of DB107 In Promising Turn-Around of Targeted Treatment to Treat Newly Diagnosed High Grade Glioma

              Details:

              DB107 (vocimagene amiretrorepvec) is a two-part cancer-selective immunotherapy comprising an investigational gene therapy treatment and an investigational small molecule, which is investigated for the treatment of newly diagnosed high grade glioma.

              Lead Product(s): Vocimagene Amiretrorepvec,Fluocytosine

              Therapeutic Area: Oncology Product Name: DB107

              Highest Development Status: Phase II/ Phase III Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable July 25, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Transgene

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag France
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Positive Readouts for Transgene’s Clinical Stage Candidates Generated by its Two Innovative Platforms, with Further Clinical Data Expected in the Second Half of 2022

              Details:

              TG6002 is novel oncolytic virus that has been engineered to combine multiple mechanisms of action. It has been designed to,selectively replicate within cancer cells. This is due to deletion of viral genes encoding TK and RR.

              Lead Product(s): TG6002,Fluocytosine

              Therapeutic Area: Oncology Product Name: TG6002

              Highest Development Status: Phase I/ Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 07, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Transgene

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag France
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Transgene Presents Initial Phase I Data of TG6002, Highlighting the Potential of the Intravenous Administration of Its Oncolytic Viruses

              Details:

              These data provide a clinical proof of concept for Transgene’s double deleted VVcopTK-RR- patented virus backbone: after IV administration, TG6002 reached the tumor, multiplied within tumor cells, and induced the local expression of its payload (the FCU1 gene).

              Lead Product(s): TG6002,Fluocytosine

              Therapeutic Area: Oncology Product Name: TG6002

              Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 09, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Transgene

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag France
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Positive Data From a Phase 1 Trial With Transgene’s Oncolytic Virus TG6002

              Details:

              The trial aims at confirming the good tolerability of ascending doses of intravenous TG6002 and at providing the first translational data from this novel route of administration.

              Lead Product(s): TG6002,Fluocytosine

              Therapeutic Area: Oncology Product Name: TG6002

              Highest Development Status: Phase I/ Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 08, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Transgene

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag France
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Transgene Receives $22.2 Million from the Sale of Part of its Minority Stake in Tasly BioPharmaceuticals

              Details:

              Transgene has been a shareholder in Tasly BioPharmaceuticals when it received shares of Tasly Biopharmaceuticals in exchange for the sale of the Greater China rights of T101 and T601, two products respectively incorporating Transgene’s TG6002 and TG1050 patented technologies.

              Lead Product(s): TG6002,Fluocytosine

              Therapeutic Area: Oncology Product Name: TG6002

              Highest Development Status: Phase I/ Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Tasly BioPharmaceuticals

              Deal Size: $22.2 million Upfront Cash: Undisclosed

              Deal Type: Financing August 04, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Aurobindo Pharma Limited

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag India
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Aurobindo Pharma Gets USFDA Nod For Flucytosine Capsules

              Details:

              Flucytosine capsules are generic version of Bausch Health's Ancobon capsules. The product will be launched in June 2020.

              Lead Product(s): Fluocytosine

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 04, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY